No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 1 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Odyssey Therapeutics, Inc. (ODTX) stock was $18.13 as of Oct 6, 2026, 4:00 PM EDT, down 13.00% from the previous close.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases.
Biotechnology · Boston, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-1.08
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.27
vs Estimate
$-0.85
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ODTX | $870.81M | $18.13 | -13.00% | N/A | N/A | N/A | N/A |
| 2SIBN | $867.03M | $19.55 | -1.31% | +36.42% | -1.46% | N/A | vs ODTX |
| 3QDEL | $857.16M | $12.57 | +3.54% | -59.33% | -38.12% | -5.68% | vs ODTX |
| 4ABUS | $884.97M | $4.48 | -4.07% | +6.59% | +2.19% | +2.93% | vs ODTX |
| 5ALMS | $855.38M | $6.93 | +1.32% | +69.72% | N/A | N/A | vs ODTX |
| 6BVS | $887.50M | $13.10 | -3.11% | +91.99% | -0.81% | N/A | vs ODTX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 4 analysts
Average Price Target
$35.75
+97.2% upside
Low
$29.00
Current
$18.13
High
$44.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.25 | $-1.08 | $-0.96 | 3 |
| Quarter ending Dec 2026 | $-1.36 | $-1.11 | $-0.85 | 3 |
| Quarter ending Mar 2027 | $-1.14 | $-1.14 | $-1.14 | 1 |
| Quarter ending Jun 2027 | $-1.19 | $-1.19 | $-1.19 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.95 | $-5.89 | $-5.17 | 4 |
| FY 2027 | $-6.65 | $-4.87 | $-3.45 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.98M | $2.98M | $2.98M | 6 |
| FY 2027 | $2.98M | $2.98M | $2.98M | 6 |
